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Background. The detection of latent tuberculosis infection (LTBI) is a major component of tuberculosis (TB) control strategies.
In addition to the tuberculosis skin test (TST), novel blood tests, based on in vitro release of IFN-c in response to
Mycobacterium tuberculosis-specific antigens ESAT-6 and CFP-10 (IGRAs), are used for TB diagnosis. However, neither IGRAs
nor the TST can separate acute TB from LTBI, and there is concern that responses in IGRAs may decline with time after
infection. We have therefore evaluated the potential of the novel antigen heparin-binding hemagglutinin (HBHA) for in vitro
detection of LTBI. Methodology and Principal Findings. HBHA was compared to purified protein derivative (PPD) and ESAT-6
in IGRAs on lymphocytes drawn from 205 individuals living in Belgium, a country with low TB prevalence, where BCG
vaccination is not routinely used. Among these subjects, 89 had active TB, 65 had LTBI, based on well-standardized TST
reactions and 51 were negative controls. HBHA was significantly more sensitive than ESAT-6 and more specific than PPD for the
detection of LTBI. PPD-based tests yielded 90.00% sensitivity and 70.00% specificity for the detection of LTBI, whereas the
sensitivity and specificity for the ESAT-6-based tests were 40.74% and 90.91%, and those for the HBHA-based tests were
92.06% and 93.88%, respectively. The QuantiFERON-TB Gold In-Tube (QFT-IT) test applied on 20 LTBI subjects yielded 50%
sensitivity. The HBHA IGRA was not influenced by prior BCG vaccination, and, in contrast to the QFT-IT test, remote (.2 years)
infections were detected as well as recent (,2 years) infections by the HBHA-specific test. Conclusions. The use of ESAT-6-
and CFP-10-based IGRAs may underestimate the incidence of LTBI, whereas the use of HBHA may combine the operational
advantages of IGRAs with high sensitivity and specificity for latent infection.
Citation: Hougardy J-M, Schepers K, Place S, Drowart A, Lechevin V, et al (2007) Heparin-Binding-Hemagglutinin-Induced IFN-c Release as a Diagnostic
Tool for Latent Tuberculosis. PLoS ONE 2(10): e926. doi:10.1371/journal.pone.0000926
INTRODUCTION
Tuberculosis (TB) remains a major health problem even in the 21
st
century, with 1.6 million deaths globally recorded in 2005 by the
World Health Organization, and more than 8.8 million new
infections [1]. As a result, approximately 2 billion individuals are
estimated to be latently infected with the causative agent,
Mycobacterium tuberculosis [2]. Most infected subjects will not develop
symptoms of the disease during their lifetime but maintain a latent
TB infection (LTBI). Although the risk of progression to active
disease is highest within the first two years of infection, LTBI
subjects remain at life-long risk of subsequently developing the
disease if not treated [3,4]. This risk is particularly high for persons
with immunosuppressive conditions, such as HIV infection,
chronic renal failure, or if placed on infliximab therapy [5–7].
LTBI subjects thus represent an important reservoir for future TB
cases, and their identification and preventive treatment or
surveillance are key elements in TB control [3–8]. By using this
strategy, eradication of TB in low-prevalence countries has been
judged by some to be a realistic goal, provided that LTBI can be
effectively diagnosed at a population-wide level [8].
In the absence of a gold standard, the most widely used diagnostic
test for LTBI remains the tuberculin skin test (TST), based on the
delayed-type hypersensitivity reaction that develops in M. tuberculosis-
infected individuals upon intradermal injection of purified protein
derivative (PPD). However, this test suffers from many limitations,
including false-negative results, especially in some high-risk groups,
and false-positive results in BCG-vaccinated individuals or in
subjects exposed to non-tuberculous mycobacteria (NTM) [9].
More recently, two tests, based on the in vitro release of IFN-c by
circulating lymphocytes (hence, interferon gamma release assays
or IGRAs) upon stimulation with the M. tuberculosis-specific
antigens early secreted antigenic target, 6 kilodaltons (ESAT-6)
and culture filtrate protein 10 kda (CFP-10) (the T-SPOT.TB test-
Oxford Immunotec, Oxford, United Kingdom and the Quanti-
FERON-TB Gold test-QFT-G, Cellestis, Victoria, Australia), have
been introduced for the diagnosis of M. tuberculosis infection
[10,11]. These IGRAs have been the subject of numerous studies,
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individuals with suspected TB [11–16], where theyhave been shown
to be sensitive and highly specific for the detection of a recent
infection. In contrast, only a few cross-sectional studies have
compared the performance of IGRAs to the TST for the diagnosis
of LTBI resulting from a remote infection [17,18]. These studies
suggest that IGRAs underestimate the true prevalence of LTBI,
especially when resulting from a remote infection, inferring that
IGRAsaremostsuitablefordetectingrecentM.tuberculosisinfections.
In this study, we assessed the diagnostic potential of a novel
mycobacterial antigen, the heparin-binding hemagglutinin
(HBHA) [19], previously shown to stimulate high levels of IFN-c
secretion by the peripheral blood lymphocytes of LTBI subjects
[20,21]. A HBHA-based IGRA was compared to those based on
PPD or ESAT-6, as well as to the QFT-IT test, on TST-defined,
recently infected healthy subjects and on healthy subjects with
a remote infection (.2 years), in comparison to non-exposed
subjects and to patients with active non-treated TB.
METHODS
Participants
235 participants were enrolled, comprising 51 negative controls
(CTRL), 82 subjects with suspected LTBI and 102 patients with
suspected active TB. All participants were sero-negative for HIV,
and none had neoplasia, malign hemopathies or had undergone
immunosuppressive treatment or solid organ transplantation, nor
were any of the women pregnant during the study period. CTRL
were defined on the basis of a negative TST and the absence of
a history of TB or of known contact with TB patients. LTBI
subjects were defined by documented TST conversion (increase in
induration size of$10 mm compared to the previous year) at the
Occupational Medicine Department (n=31) or by a diameter of
induration of the TST$10 mm for household contacts of active
TB case patients (n=21) or by the clinical data and/or TST result
at the time of employment as a health care worker, as assessed by
the Occupational Medicine Department (n=13). Among the 82
subjects initially enrolled, results from 16 of them were rejected
because the retrospective analysis of the clinical data indicated that
these subjects did not fulfill the strict criteria for the LTBI diagnosis,
and one was rejected for a technical problem in the IGRA. TST
consisted of an intradermal injection of 2 tuberculin units (TU) of
PPD (RT23, Statens Serum Institute, Copenhagen, Denmark), and
the results of the TST were read 48 to 72 hours later. Blood samples
were collected within 6 months of the TST for 34 subjects
considered as recent TST converters (21 TST
+ household contacts
and 13 health careworkerswith a TST conversion). Fortheother 31
LTBI subjects included in the study, blood samples were collected at
least 2 years after the TST (mean time between TST and IGRA:
14.23 years,SEM:9.68 years).For17amongthem,2to6sequential
blood tests were performed (see Table 1).
Active TB cases were all confirmed on the basis of at least one of
the criteria defined by the American Thoracic Society [22]:
a positive smear and/or a positive culture, the presence of
granuloma in a biopsy, a positive polymerase chain reaction or
a clinical suspicion with favorable clinical response upon
treatment. Of the 102 suspected TB patients initially enrolled,
13 were rejected for absence of formal proof of active TB as
defined by these criteria. Among the remaining 89 TB patients, 58
presented with pulmonary TB, and 31 with extra-pulmonary TB.
Of these latter, 13 had pleural effusions, whereas the others
presented with adenopathies (n=5), urinary and/or abdominal
TB (n=7), pericarditis (n=1), uveitis and pulmonary TB (n=1),
or disseminated miliary TB (n=4). Blood samples were taken
before or during the first week of chemotherapy. All the study
participants were living in Belgium at the time of enrolment. Blood
samples were collected from 1999 through to 2007. Demographic
data are given in Table 2. The study was approved by the Ethical
Committee of the Universite ´ Libre de Bruxelles and by the Ethical
Committees from three different hospitals where the patients were
recruited. Informed consent was given by all participants.
Antigens and antigen-specific IFN-c determinations
HBHA was purified from Mycobacterium bovis BCG as previously
described [19,20]. PPD (batch RT49) and recombinant ESAT-6
were obtained from the Statens Serum Institute, Copenhagen.
PBMC were purified from fresh blood samples and in vitro
stimulated as previously described [20,21] with 2 mg/ml HBHA,
4 mg/ml PPD or 10 mg/ml ESAT-6. The IFN-c concentrations
Table 1. Longitudinal follow-up of LTBI with the HBHA-IGRA
test
......................................................................
LTBI
subject nu
Year of
diagnosis Year of HBHA IGRA test
2000 2001 2002 2003 2006 2007
1 1979 +++ ++
2 1979 ++
3 1989 ++
4 1992 ++++++
5 1993 ++ +
6 1994 ++
7 2000 ++
8 2001 ++
9 1986 +++
10 1985 ++
11 1972 ++
12 1978 ++
13 1995 ++ +
14 2000 ++ +
15 2000 ++
16 1990 ++
17 1985 ++
doi:10.1371/journal.pone.0000926.t001
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Table 2. Characteristics of the included subjects
......................................................................
CTRL LTBI TB
N5 1 6 5 8 9
% women 72.5 61.5 20.7
Median age (yrs) 36.46 38.15 36.10
Min-Max age 23.13–80.95 13.65–60.02 17.1–80.0
Ethnic distribution (%)
Caucasian 94.2 66.1 56.2
North African 1.9 23.1 27.0
Central African 0.0 4.6 14.6
Asian 3.9 0.0 1.1
Miscellaneous 0.0 6.2 1.1
doi:10.1371/journal.pone.0000926.t002
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HBHA-Induced IFN-c
PLoS ONE | www.plosone.org 2 October 2007 | Issue 10 | e926were measured in 4-day cell culture supernatants by ELISA as
previously described [20]. According to the manufacturer’s
instructions (www.cellestis.com), the QFT-G In-Tube (QFT-IT)
assay was performed on whole blood, in contrast to the in-house
IGRAs, and the cut-off value for a positive test was defined as IFN-
c$0.35 IU/ml. For stimulation with the protein antigens (HBHA,
ESAT-6, or PPD), we have chosen to incubate the PBMC for
96 h, rather than for 24 h, as recommended for the commercial
QFT-IT, for two main reasons. Since proteic antigens were used
for the ELISAs rather than peptides, as in QFT-IT, it is thought
that they require some time for processing by antigen-presenting
cells before they can stimulate T cells. Furthermore, prolonged
incubation with antigen has recently been shown to increase the
sensitivity of T cell tests for the detection of LTBI [23], probably
because short in vitro incubation times in the presence of antigen
preferentially result in the detection of effector T cells, whereas
longer incubation times favor the detection of both effector and
memory T cells [17,18].
Statistical analyses
Differences between the groups were assessed by the non-parametric
Kruskal-Wallis test followed by the Dunn’s multiple comparison test,
or by the non-parametric Mann-Whitney U test. Receiver
Operating Characteristic (ROC) curves were established for each
mycobacterial antigen, and the areas under the curves (AUC) were
comparedtoeachotherbyusingthefollowingequation:z=|AUC1-
AUC2|/!(Std Err1
2+Std Err2
2), with z.1.96 for a probability of
0.05 for making a type I error in rejecting the hypothesis that the 2
curves are similar. Correlation was analyzed by the non-parametric
Spearman test and by a linear regression analysis. A value of P,0.05
was considered to be significant. All results were obtained with the
Graphpad Prism Software version 4.0b.
RESULTS
PPD-induced IFN-c secretion
Since the LTBI subjects were defined on the basis of a positive
TST reaction, we first evaluated the in vitro PPD-induced IFN-c
secretion by PBMC from LTBI subjects and TB patients
compared to that from CTRL. As shown in Fig. 1A, LTBI
subjects and TB patients secreted significantly more IFN-c in
response to PPD than CTRL (medians 15.83 ng/ml and 6.84 ng/
ml, respectively, versus 0.23 ng/ml; P,0.001), whereas the
median level of IFN-c produced was not significantly different
between the LTBI and TB groups. To evaluate the sensitivity and
specificity of the in vitro PPD-IFN-c test for the discrimination of
LTBI from CTRL, a ROC curve was established and the AUC
determined. As shown in Fig. 1B, the AUC was 0.89 (95% IC :
0.83–0.95), indicating both a good global accuracy of the PPD-
induced IFN-c production for discriminating LTBI from CTRL,
and good agreement between a positive TST reaction and
elevated PPD-specific IFN-c secretion. A similar analysis compar-
ing the TB patients with the CTRL gave an AUC of 0.80 (95%
IC: 0.73–0.87). Using the ROC analysis, a cut-off IFN-c
concentration of 0.8 ng/ml was determined as being the most
discriminatory between LTBI and TB versus the CTRL.
Based on this value, the PPD-induced-IFN-c responses allowed
us to differentiate LTBI from CTRL with a 90.0% sensitivity and
a 70.0% specificity and to differentiate TB patients from the
CTRL with a 75.0% sensitivity and a 70.0% specificity. The low
specificity was a consequence of the positive responses from some
CTRL, apparently mostly due to BCG vaccination (see below).
Higher specificity of this test for LTBI may only be obtained at the
expense of lower sensitivity.
ESAT-6-induced IFN-c secretion
Since ESAT-6 is largely restricted to members of the M. tuberculosis
complex, measuring the IFN-c responses to ESAT-6 should improve
the specificity compared to the PPD-induced IFN-c responses [24].
We therefore evaluated the ESAT-6-specific IFN-c results in the
three study groups, using the same methodology. The results shown
in Fig. 1C confirmed that LTBI subjects and TB patients secrete
higher amounts of IFN-c in response to ESAT-6 than the CTRL
(medians of 0.07 ng/ml for TB and below detectable levels for the
two other groups; Fig. 1C). The ROC analysis of the LTBI and TB
compared to the CTRL provided an AUC of only 0.70 (95% IC:
0.55–0.84) for LTBI and of 0.81 (95% IC: 0.70–0.91) for TB
(Fig. 1D), compared to 0.89 and 0.80, respectively, obtained for the
PPD-induced IFN-c secretions. Comparisons by determining the z
value of the curves obtained for ESAT-6 and PPD for LTBI
indicated a lower global accuracy of ESAT-6 IGRA compared to
PPD IGRA for the detection of LTBI (z=2.41; P,0.05).
Using the ROC curves, a threshold of 0.040 ng/ml of IFN-c was
determined to best differentiate LTBI and TB from the CTRL
group. Based on this value, the ESAT-6-induced-IFN-c responses
allowed us to differentiate LTBI from CTRL with a 40.74%
sensitivity and a 90.91% specificity and to differentiate TB patients
from the CTRL with a 60.00% sensitivity and a 90.91% specificity.
The last twenty LTBI subjects included in this study were also
tested by using the QFT-IT test, as this test includes overlapping
peptides of the M. tuberculosis-specific CFP-10 and TB 7.7 antigens
in addition to ESAT-6 for lymphocyte stimulation (www.cellestis.
com), which should increase the sensitivity of the blood test
compared to stimulation by ESAT-6 alone. Ten out of the 20
subjects tested were positive with the QFT-IT test (IFN-c$0.35
UI), compared to 6 with the in-house ESAT-6 test, indicating that
the QFT-IT test does appear to be more sensitive for the detection
of LTBI than a test based on ESAT-6 alone. The sensitivity of the
QFT-IT test remained nevertheless rather low for the detection of
LTBI in this sampled population.
HBHA-induced IFN-c secretions
Given the low specificity of the PPD IFN-c test and the low
sensitivity of the ESAT-6 IFN-c test for the detection of LTBI in
this population, we assessed the diagnostic value of HBHA, a novel
antigen, previously shown to induce significantly higher IFN-c
production by PBMC from LTBI compared to controls and TB
patients [20,21]. The previous findings were confirmed here
(medians of 1.727 and 0.120 ng/ml for LTBI and TB, re-
spectively; and below detectable median levels for the CTRL;
P,0.001 for CTRL and LTBI; P,0.001 for CTRL and TB)
(Fig. 1E). ROC analyses of LTBI and TB to CTRL gave an AUC
of 0.97 (95% IC: 0.95–0.99) and 0.80 (95% IC: 0.72–0.87),
respectively (Fig.1F). The AUC for the LTBI was significantly
different from that obtained with PPD (z=2.38 ; P,0.05), and
from that obtained with ESAT-6 (z=2.41 ; P,0.05), suggestive of
a better global accuracy of HBHA-induced IFN-c production
compared to PPD- and ESAT-6-induced IFN-c concentrations for
the detection of LTBI. The cut-off value determined by the ROC
analysis was 0.100 ng/ml, yielding a sensitivity of 92.06% and
a specificity of 93.88% for the detection of LTBI. For TB, the
sensitivity and specificity were 55.29% and 93.88%, respectively.
However, due to the ELISA variation coefficient, 1.5% of the
results obtained for LTBI and 4.5% of those obtained for TB may
perhaps be considered as being indeterminate, as they fell between
0.080 and 0.120 ng/ml. Among the three antigens tested, HBHA
provided thus the best overall diagnostic value for the detection of
LTBI. Interestingly, among the 20 LTBI subjects that were also
HBHA-Induced IFN-c
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e926Figure 1. PPD, ESAT-6, and HBHA-induced IFN-c concentrations and ROC analysis of the results. Results of the IFN-c ELISA obtained for three
different groups of subjects: non-infected controls (CTRL), subjects with latent M. tuberculosis infection (LTBI) and patients with active tuberculosis
(TB) are represented on the left part of the figure. PBMC were in vitro stimulated with different antigens, PPD (A), ESAT-6 (C) and HBHA (E) and the
IFN-c concentrations were measured in 96 h cell culture supernatants. The horizontal dotted lines represent the cut-off for positive values as
determined by ROC curves analysis, whereas the horizontal filled lines represent the medians of the results. ROC curves established for each antigen
are represented on the right panels (PPD, B; ESAT-6, D; HBHA, F). The filled lines represent the curve established for LTBI compared to CTRL, whereas
the dotted lines are those established for TB compared to CTRL. *, P,0.05; ***, P,0.001.
doi:10.1371/journal.pone.0000926.g001
HBHA-Induced IFN-c
PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e926tested with the QFT-IT test, 17 scored positive for HBHA-induced
IFN-c, compared to only 10 positives for the QFT-IT test (see
above).
The LTBI subjects were subdivided in two groups as defined in
the Materials and Methods section. For the first group considered
as being recently infected (n=32), the blood sample was obtained
within a maximum of 6 months after a TST conversion (21
household contacts and 11 health care workers). As a TST is
performed once a year in health care workers, it is likely that the
time elapsed between infection and blood sampling was at most
2 years. The second group of LTBI (n=31) was considered to
result from an infection in the more distant past, as their TST
conversion had occurred more than 2 years before blood sampling
(mean and SEM of the time between the TST and the blood
sampling: 14.23 years, 9.68 years). No significant differences in
the HBHA-induced IFN-c concentrations were found between the
two sub-groups of LTBI subjects (Fig. 2). The HBHA IGRA
yielded sensitivities higher than 90% for the detection of both
recently infected subjects and those with LTBI secondary to
a remote M. tuberculosis infection (sensitivities of 90.62% and
93.54% for recent and remote infection, respectively). Among the
20 subjects tested with the QFT-IT test, most LTBI (n=17) were
the result of a remote infection. Among those 17 LTBI only 7 were
positive in the QFT-IT test, whereas 15 were positive in the
HBHA IGRA. In contrast, among the 3 recent TST converters, all
three were positive in the QFT-IT test and two were positive in the
HBHA IGRA. When these 17 LTBI subjects were followed by
a longitudinal analysis, using 2 to 6 HBHA-based IGRAs spread
over a total of 6 years, all were found positive at each time point
(Table 1).
Influence of BCG vaccination on the IFN-c secretions
Although BCG vaccination is not routinely used in Belgium,
approximately half of the CTRL in this study had nevertheless
been vaccinated for various reasons more than 15 years before
their inclusion in this study. This allowed us to evaluate the
potential influence of BCG vaccination on the antigen-induced
IFN-c concentrations among the CTRL. PPD more frequently
induced IFN-c secretion by PBMC from BCG-vaccinated subjects
(10 out of 22) than from non-vaccinated individuals (5 out of 26).
This was not the case for the HBHA- (only 2 CTRL with an
HBHA-induced IFN-c secretion.0.1 ng/ml, one vaccinated and
the other non-vaccinated) and for the ESAT-6-induced IFN-c
production (none in the CTRL).
A proportion of the LTBI subjects had also been previously
vaccinated with BCG (n=26). The comparison of the antigen-
induced IFN-c concentrations between the vaccinated LTBI and
the non-vaccinated LTBI did not reveal significant differences for
the IFN-c responses induced by PPD-, ESAT-6 or HBHA.
Pair-wise comparisons of the IFN-c secretions
induced by the different mycobacterial antigens
When the IFN-c responses to PPD and ESAT-6 were compared
pair-wise to the HBHA-specific responses, a moderate correlation
was found for HBHA to PPD both in LTBI subjects (r=0.55,
P,0.0001) (Fig. 3A) and in TB patients (r=0.71, P,0.0001)
(Fig. 3B). A low or moderate correlation was found for HBHA to
ESAT-6 in LTBI subjects (r=0.41, P=0.018) (Fig. 3C) and in TB
patients (r=0.58, P=0.0002) (Fig. 3D).
Combining the values of the PPD- and the HBHA-induced
IFN-c secretions would not improve the diagnostic power for M.
tuberculosis infection because of the low specificity of the PPD-
specific response. Instead, we analyzed whether combining
HBHA-induced and ESAT-6-induced IFN-c secretions may help
to increase sensitivity, while maintaining specificity at a high level.
As shown in Fig. 3C, this combination did not increase the
sensitivity for the LTBI subjects, as none of the LTBI subjects with
a negative HBHA test was positive in the ESAT-6 test. In contrast,
45.16% of the LTBI subjects secreted IFN-c in response to HBHA
and not in response to ESAT-6 (Fig. 3C). However, combining
HBHA-induced and ESAT-6-induced IFN-c secretions allowed us
to detect slightly more TB patients over the HBHA response
alone, as 4/37 TB patients were only positive in the ESAT-6 test,
and 5/37 were only positive in the HBHA test (Fig. 3D).
DISCUSSION
In this study, we examined the diagnostic value of HBHA, a novel
mycobacterial antigen, for the detection of LTBI in a low-
incidence country, where infection by NTM is rare and where
BCG vaccination is not routinely used. We found that the in vitro
HBHA-specific IGRA yielded a sensitivity of 92.06% and
a specificity of 93.88% for the detection of LTBI, a substantially
better sensitivity in this population than an ESAT-6-specific IGRA
(40.74%, with a 90.91% specificity) and a substantially better
specificity than a PPD-specific IFN-c test (70%, with a similar
sensitivity, 90.0%). In contrast, the ESAT-6 and HBHA responses
were not significantly different for the diagnosis of acute TB.
HBHA performed relatively poorly for the diagnosis of acute TB,
as shown previously [21]. This is due at least partly to the
induction of HBHA-specific regulatory T cells during active TB
[25]. Combining the ESAT-6 results with the HBHA results did
not improve sensitivity for LTBI. Low sensitivity of the ESAT-6
IGRA for the detection of LTBI, especially if carried out a long
time after the point-source exposure has already been reported as
Figure 2. Comparison between the HBHA-induced IFN-c concentra-
tions in recently and in remote M. tuberculosis infected LTBI
subjects. Blood samples were collected from LTBI subjects during the
first two years (recent) or after two years (remote) of their TST
conversion. Their PBMC were in vitro stimulated with HBHA, and the
IFN-c concentrations were measured in 96 h cell culture supernatants.
No significant difference in the IFN-c concentrations measured in the
two groups was noted. The horizontal dotted line indicates the
positivity cut-off of the test, and the horizontal filled lines indicate the
medians.
doi:10.1371/journal.pone.0000926.g002
HBHA-Induced IFN-c
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[26]. Similarly, although tested here only on 20 subjects, the QFT-
IT test detected only 50% LTBI, compared to 85% detected in
this series by the HBHA IGRA. The difference of performance
between the two tests was especially pronounced when LTBI
presumed to result from exposure in the remote past were
diagnosed. In contrast, both tests were equally effective in recent
TST converters.
An important consideration in this study is obviously the
definition of the LTBI subjects enrolled. We have chosen rather
stringent TST positive criteria, so that it is unlikely that the TST
+
subjects were false positives because of NTM infection, although
occasional mis-diagnosis of TST positivity due to NTM infection
can obviously not formally be excluded. In addition, the study was
carried out in Belgium, a country with a low TB incidence (10.9/
100,000; www.fares.be). True LTBI resulting from remote
Figure 3. Correlations between the IFN-c concentrations induced by different mycobacterial antigens. Results obtained for LTBI are represented
on the left panels (A, C), and those obtained for TB are on the right panels (B, D). The degree of correlation between the in vitro-induced IFN-c
concentrations by the different mycobacterial antigens is represented for PPD and HBHA (A and B) and for ESAT-6 and HBHA (C and D). The dotted
lines indicate the positivity cut-off for each test.
doi:10.1371/journal.pone.0000926.g003
HBHA-Induced IFN-c
PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e926exposure can only be studied in low- or intermediate-incidence
areas, where re-exposure to M. tuberculosis is rare.
The influence of a previous BCG vaccination that might have
given rise to false-positive TST results is also highly improbable,
since 31 out of the 65 LTBI subjects were identified by the
Occupational Medicine Department because of a TST conversion
in the absence of a BCG vaccination at the time of the TST
conversion. Furthermore, TST reactivity after BCG vaccination
rarely lasts for more than 10 years in the absence of subsequent M.
tuberculosis infection [27], making it also unlikely that the TST
positivity of the remotely infected subjects was due to BCG
vaccination in their childhood. In Belgium BCG vaccination is not
routinely used, and only 7 of the subjects had been previously
vaccinated, more than 15 years before their enrolment in the
study. The contention that the HBHA response was not
confounded by BCG vaccination is consistent with the fact that
in the control group, no significant difference in the numbers of
HBHA-responders was found between the vaccinated and the
non-vaccinated subjects. In contrast, a higher number of positives
were found in the vaccinated control group (10 out of 22)
compared to the non-vaccinated group (5 out of 26) when the PPD
responses were examined, probably accounting for the lower
specificity of the PPD IGRA compared to the HBHA IGRA. The
absence of influence of a previous BCG vaccination on the HBHA
IGRA might be surprising, as HBHA is produced by all members
of the M. tuberculosis complex, including M. bovis BCG [28].
Although the reasons for this difference between BCG vaccination
and M. tuberculosis infection are not yet known, there are
preliminary indications that the expression levels of the HBHA
encoding gene are much lower in BCG than in M. tuberculosis,
especially within cells in which the mycobacteria reside during
latency (C. L., unpublished).
In this study, only the RT23 PPD was used for the TST, as this
is the most widely used PPD in Europe. Previous studies have
shown that the pattern of reactivity obtained with 2 TU of RT23
PPD is similar to that obtained with 5 TU of a different PPD, such
as Tubersol [29]. Therefore, the findings reported here are
expected to be similar if PPD preparations other than RT23 would
have been used in the TST.
A major advantage of the HBHA IGRA reported here is the
ability to detect LTBI resulting from a remote M. tuberculosis
exposure. This may have practical consequences for TB control
strategies. Although diagnosis and treatment of recently infected
subjects deserves the utmost priority, because these subjects are at
highest risk of developing active TB, detection of LTBI resulting
from a remote infection may also be important. This is the case
especially for health care workers [4] and for immunocompro-
mised individuals, as immunosuppression because of either
infection with HIV or of immunosuppressive treatment sub-
stantially increases the risk of TB reactivation [5–7]. Finally, in the
long run, if eradication of TB is considered to be a realistic goal,
especially in low-prevalence countries, LTBI subjects will have to
be effectively diagnosed at a population-wide level [3,6,8].
A limitation of the present study is the relatively small sample
size in the cross-sectional study design. However, a longitudinal
follow-up performed for 17 LTBI subjects suggests that the
subjects categorized as LTBI resulting from a remote infection
remained positive and were thus true LTBI cases.
In conclusion, we provide here evidence that a HBHA-based
IGRA may be useful for the detection of LTBI and is both
substantially more sensitive for LTBI than an ESAT-6-based test,
and substantially more specific than a PPD-based test. In addition,
it is able to detect LTBI subjects with a remote infection that were
missed by the QFT-IT test, a test proposed by the US Centers for
Disease Control to replace the TST [30]. These LTBI subjects are
important to detect in view of the increasing number of patients
that require immunosuppressive therapy or that are infected with
HIV and should therefore receive preventive anti-tuberculous
treatment with high priority [6]. Thus, the current ESAT-6- and/
or CFP-10-based IFN-c IGRAs may underestimate LTBI, and our
results indicate that the replacement of the TST by IGRAs should
be considered with caution. The use of a HBHA IGRA may
provide an attractive solution, by combining the operational
advantages of an in vitro IFN-c test with high sensitivity and
specificity for LTBI.
However, one of the current challenges is that HBHA is
a methylated antigen, and that the methylation is important for
the HBHA-specific T-cell responses [21]. When recombinant,
non-methylated HBHA is used instead of native, methylated
HBHA, the sensitivity of the IGRA for the detection of LTBI
decreases to 69.44% with a 88.46% specificity (data not shown).
HBHA is thus not yet commercially available. However, a product
development plan is currently being worked out, which should also
allow us to test the diagnostic potential of this antigen as a skin test
reagent. Furthermore, a prospective head-to-head comparison of
the HBHA IGRA and the TST for the detection of LTBI among
health care workers in Belgium will begin soon, as well as studies in
immuno-suppressed populations, such as HIV-infected patients
and patients starting infliximab therapy.
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